152317-89-0
基本信息
1,3-Propanediamine, N1-[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]-N3-(1,4,5,6-tetrahydro-2-pyrimidinyl)-
物理化学性质
| 储存条件 | -20°C储存 |
| 溶解度 | 溶于二甲基亚砜 |
常见问题列表
|
5-HT 1B Receptor 1.7 nM (IC 50 , in HEK 293 cell) |
5-HT 1D Receptor 1.3 nM (IC 50 , in HEK 293 cell) |
In vitro, alniditan exhibits little vasoconstrictive effects on the rat basilar artery, although at a very high concentration 1 mM, alniditan causes intensive constriction, most likely through a mechanism independent from 5-HT receptor activation. Alniditan is 10 times more potent than sumatriptan at the h5-HT1B receptor, and twice as potent at the h5-HT 1D receptor.
The intraperitoneal administration of alniditan ED 50 =9 μg/kg and sumatriptan ED 50 =70 μg kg dose dependly reduces [ 125 I]-BSA extravasation in the rat meninges when done 30 min before stimulation. The estimated ED values for alniditan are 9 μg/kg in the absence and 190 μg/kg in the presence of GR 127935. Alniditan (3, 10, 30 and 100 μg/kg) produces a dose-dependent increase in the arteriovenous oxygen saturation difference, which seems to be attenuated in animals treated with GR127935. Alniditan dose-dependently decreases total carotid and arteriovenous anastomotic blood flow and concomitant conductance values; nutrient blood flow and conductance increase. Alniditan also produces significant increases in vascular conductance to the skin, ear, bone, salivary gland, fat, tongue, brain and dura mater; no changes are observed in the muscles and eyes.